Enfusion, Inc. (NYSE:ENFN) Receives Consensus Recommendation of “Reduce” from Analysts

Shares of Enfusion, Inc. (NYSE:ENFN) have earned a consensus recommendation of “Reduce” from the six analysts that are covering the stock, MarketBeat.com reports. Three research analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and two have issued a buy recommendation on the company. The average 12 month price target among brokers that have covered the stock in the last year is $10.25.

Several research firms recently weighed in on ENFN. Piper Sandler raised their target price on shares of Enfusion from $10.00 to $11.50 and gave the company a “neutral” rating in a research note on Monday, December 23rd. Stifel Nicolaus upped their price target on shares of Enfusion from $11.00 to $13.00 and gave the company a “buy” rating in a research note on Wednesday, December 18th.

Enfusion Price Performance

Shares of NYSE ENFN opened at $9.97 on Friday. The stock has a market capitalization of $1.28 billion, a price-to-earnings ratio of 249.31, a PEG ratio of 3.98 and a beta of 0.95. Enfusion has a fifty-two week low of $7.52 and a fifty-two week high of $11.38. The business has a 50-day moving average of $10.11 and a 200-day moving average of $9.20.

Insider Transactions at Enfusion

In other Enfusion news, COO Neal Pawar sold 21,801 shares of the business’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $10.03, for a total transaction of $218,664.03. Following the sale, the chief operating officer now owns 1,143,544 shares of the company’s stock, valued at approximately $11,469,746.32. The trade was a 1.87 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Bradley Herring sold 24,443 shares of the company’s stock in a transaction on Friday, December 20th. The stock was sold at an average price of $10.61, for a total transaction of $259,340.23. Following the transaction, the chief financial officer now owns 270,503 shares of the company’s stock, valued at $2,870,036.83. This trade represents a 8.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 56,404 shares of company stock valued at $580,130. Company insiders own 36.44% of the company’s stock.

Hedge Funds Weigh In On Enfusion

Large investors have recently bought and sold shares of the company. Geode Capital Management LLC raised its position in Enfusion by 7.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,029,366 shares of the company’s stock worth $9,770,000 after purchasing an additional 70,367 shares during the last quarter. Scalar Gauge Management LLC raised its position in shares of Enfusion by 21.8% during the second quarter. Scalar Gauge Management LLC now owns 613,513 shares of the company’s stock worth $5,227,000 after acquiring an additional 110,000 shares during the last quarter. Wellington Management Group LLP raised its position in shares of Enfusion by 6.7% during the third quarter. Wellington Management Group LLP now owns 976,296 shares of the company’s stock worth $9,265,000 after acquiring an additional 61,032 shares during the last quarter. Renaissance Technologies LLC lifted its stake in shares of Enfusion by 167.6% in the second quarter. Renaissance Technologies LLC now owns 97,100 shares of the company’s stock worth $827,000 after acquiring an additional 60,811 shares during the period. Finally, Barclays PLC boosted its holdings in Enfusion by 251.4% in the third quarter. Barclays PLC now owns 86,039 shares of the company’s stock valued at $817,000 after acquiring an additional 61,554 shares during the last quarter. 81.05% of the stock is currently owned by institutional investors.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.